Cristiana Pires, Asgard Therapeutics CEO

Swedish biotech rais­es €30M Se­ries A to de­vel­op off-the-shelf gene ther­a­py for sol­id tu­mors

As it ad­vances its in vi­vo cell re­pro­gram­ming plat­form, As­gard Ther­a­peu­tics has raised €30 mil­lion ($32.8 mil­lion) with the help of sev­er­al Big Phar­ma ven­ture arms.

New in­vestors John­son & John­son In­no­va­tion – JJDC and RV In­vest co-led the Se­ries A, with sup­port from ex­ist­ing in­vestors No­vo Hold­ings, Boehringer In­gel­heim Ven­ture Fund and In­dus­tri­fonden. The pro­ceeds will be used to progress As­gard’s lead pro­gram, ex­pand its R&D team and sup­port work on new drug modal­i­ties and de­liv­ery plat­forms, per a Thurs­day re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.